The latest price target for Standard BioTools (NASDAQ:LAB) was reported by TD Cowen on August 1, 2024. The analyst firm set a price target for $2.75 expecting LAB to rise to within 12 months (a possible 37.49% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Standard BioTools (NASDAQ:LAB) was provided by TD Cowen, and Standard BioTools maintained their buy rating.

There is no last upgrade for Standard BioTools

There is no last downgrade for Standard BioTools.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Standard BioTools, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Standard BioTools was filed on August 1, 2024 so you should expect the next rating to be made available sometime around August 1, 2025.

While ratings are subjective and will change, the latest Standard BioTools (LAB) rating was a maintained with a price target of $3.50 to $2.75. The current price Standard BioTools (LAB) is trading at is $2.00, which is out of the analyst’s predicted range.